Dear students,
The Sagol School of Neoroscience would like to offer the first year direct Ph.D
students of the IDPN to perform a three months rotation (full time) during the coming
summer in one of the neuroscience companies mentioned below. This could be a great
opportunity to get experience in the industrial environment, join the researchers'
teams in one of the companies, create networking and see how they think and perform
research in the industry.
There are names and links to the companies that can offer projects if one of the
student will express interest. We advice you to look at the School's website as the
list of updated projects will appear there (more projects will be added in the
future).
During the rotation the PhD scholarship will be paid as usual.
List of Industry-Academy projects offered - summer 2013
Company #1: Alpha-Omega, Nazareth
Microelectronic recording and neuroscience technology
http://www.alphaomega-eng.com/
Company #2: HeadSense, Natanya
.‫ מבוסס על עיבוד אותות אקוסטיים‬,‫פולשני‬-‫גולגלתי לא‬-‫חברת הדסנס מדיקל מפתחת מד לחץ תוך‬
‫ החברה עומדת לפני התחלת מכירות‬.‫ ותוצאות טובות במספר ניסויים קליניים‬,‫לחברה מוצר עובד‬
.‫ראשונות של המוצר‬
http://www.head-sense-med.com/
Company #3: NasVax, Ness Ziona
NasVax develops anti CD3 monoclonal antibody for immunotherapeutic treatment of
inflammation and BBS-based monoclonal antibody for AD
http://www.nasvax.com
Company #4: Bioimage, Tel Aviv
MRI research and consulting.
Company #5: BrainStorm, Jerusalem/Petach Tikva
BrainStorm Cell Therapeutics Ltd. is a biotechnology company developing innovative,
autologous stem cell therapies for highly debilitating neurodegenerative diseases such
as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease),
multiple Sclerosis (MS) and Parkinson's Disease (PD).
The company's core stem cell technology is a proprietary process for propagation of
autologous adult bone marrow Mesenchymal Stem Cells (MSC), inducing them to
differentiate into supportive neurological cells (NeuroTrophic factor-secreting cells,
or "MSC-NTF")' and transplanting these cells at, or near, the site of damage. We are
currently conducting a Phase 1/11 clinical trial in ALS patients at the Hadassah
Medical Center in Jerusalem and hope to begin a Phase II trial in the USA in 2013,
pending FDA approval.
http://www.brainstorm-cell.com/
Company #6: Neuronix, Yokneam
The company develops a therapy for mild to moderate Alzheimer's disease which is based on
the combination of electromagnetic stimulation of affected brain regions (by rTMS) with
cognitive training directed at specific brain regions affected by Alzheimer’s disease. The
stimulation induces LTP (Long-Term Potentiation), which is associated with learning and
memory processes, and results in a measurable cognitive improvement after just a few weeks
of treatment.
http://www.neuronixmedical.com/
Company #7: IBM research labs, Tel Aviv
Company #8: Neuroderm, Ness Ziona
Neuroderm reformulates and/or co-formulates well established drugs to enable new
routes of administration that achieve a better, or a new, clinical effect. The company
focuses on CNS diseases and its leading products include novel dermal delivery for
the treatment of Parkinson’s disease, ADD/ADHD and other CNS disorders and
diseases
NeuroDerm selected diseases and drugs where bio-availability of current therapies
was identified as the major impediment to a better clinical efficacy, where the
reformulation and/or co-formulation of existing drugs yield a unique effect.
http://www.neuroderm.com/